Author Question: The transcutaneous blood gas electrode should not be placed on the: a. chest. b. abdomen. c. ... (Read 11 times)

wenmo

  • Hero Member
  • *****
  • Posts: 540
The transcutaneous blood gas electrode should not be placed on the:
 
  a. chest.
  b. abdomen.
  c. lower back.
  d. thigh.

Question 2

In which of the following patients would transcutaneous blood gas monitoring most likely pro-vide inaccurate or erroneous results?
 
  a. Newborn infant with respiratory distress syndrome (RDS)
  b. Patient with hypoxemia
  c. Patient with a hyperpyrexia
  d. Patient in hypovolemic shock



rosiehomeworddo

  • Sr. Member
  • ****
  • Posts: 306
Answer to Question 1

ANS: D
The most common sites for electrode placement are the abdomen, chest, and lower back.

Answer to Question 2

ANS: D
This is because accurate transcutaneous measures require adequate skin perfusion. Low cardiac output, shock, and dehydration all cause peripheral vasoconstriction and impair capillary flow, which lowers the PtcO2 level.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question


 

Did you know?

Fewer than 10% of babies are born on their exact due dates, 50% are born within 1 week of the due date, and 90% are born within 2 weeks of the date.

Did you know?

Glaucoma is a leading cause of blindness. As of yet, there is no cure. Everyone is at risk, and there may be no warning signs. It is six to eight times more common in African Americans than in whites. The best and most effective way to detect glaucoma is to receive a dilated eye examination.

Did you know?

Although not all of the following muscle groups are commonly used, intramuscular injections may be given into the abdominals, biceps, calves, deltoids, gluteals, laterals, pectorals, quadriceps, trapezoids, and triceps.

Did you know?

On average, someone in the United States has a stroke about every 40 seconds. This is about 795,000 people per year.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library